Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease

Drugs and Aging

Volumn 12, Issue 2, 1998, Pages 129-137

  Ikeda, Akihiko ^a   Nishimura, Koichi ^a   Izumi, Takateru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; AMOXICILLIN; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXYCYCLINE; ERYTHROMYCIN; FORMOTEROL; GLUCOCORTICOID; IPRATROPIUM BROMIDE; METHYLPREDNISOLONE; OXITROPIUM BROMIDE; SALBUTAMOL; TERBUTALINE; THEOPHYLLINE;

AGED; ASTHMA; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG USE; FEVER; HUMAN; HYPOKALEMIA; HYPOXEMIA; INHALATIONAL DRUG ADMINISTRATION; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; METERED DOSE INHALER; NEBULIZER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; TREMOR;

ACETYLCYSTEINE; ACUTE DISEASE; AGED; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; LUNG DISEASES, OBSTRUCTIVE;

EID: 0031895342     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812020-00005     Document Type: Review

References (67)

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (5 Pt 2): S77-121
2. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-420
3. Curtis JR, Hudson LD. Emergent assessment and management of acute respiratory failure in COPD. Clin Chest Med 1994; 15: 418-500
4. Stefano ADI, Turato G, Maestrelli P, et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med 1996; 153: 629-32
5. Saetta M, Stefano ADI, Maestrelli P, et al. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy 1996; 26: 766-74
6. Hagedorn SD. Acute exacerbations of COPD. Postgrad Med 1992; 91: 105-7, 110-2
7. Dulfano MJ, Glass P. The bronchodilator effects of terbutaline: route of administration and patterns of response. Ann Allergy 1976; 37: 357-66
8. van Schayck CP, Folgering H, Harbers H, et al. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax 1991; 46: 355-9
9. Lipworth BJ, Clark RA, Dhillon DP, et al. Comparison of β-adrenoceptor responsiveness following prolonged treatment with low and high doses of inhaled terbutaline in chronic obstructive pulmonary disease. Am Rev Respir Dis 1990; 142: 338-42
10. Turner JR, Corkery KJ, Eckman D, et al. Equivalence of continuous flow nebulizer and metered-dose inhaler with reservoir bag for treatment of acute airflow obstruction. Chest 1988; 93: 476-81
11. Fuller HD, Dolovich MB, Posmituck G, et al. Pressurized aerosol versus jet aerosol delivery to mechanically ventilated patients: comparison of dose to the lungs. Am Rev Respir Dis 1990; 141: 164-8
12. Gross N, Bankwala Z. Effects of anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease: comparison with a beta-adrenergic agent. Am Rev Respir Dis 1987; 136: 1091-4
13. Conradson TB, Eklund G, Olofsson B, et al. Arrhythmogenicity from combined bronchodilator therapy in patients with obstructive lung disease and concomitant ischemic heart disease. Chest 1987; 91: 5-9
14. Sly RM, Jenne JW, Cohn J. Toxicity of beta-adrenergic drugs. In: Jenne JW, Murphy S, editors. Lung biology in health and disease. Vol. 31. Drug therapy for asthma: research and clinical practice. New York: Marcel Dekker, 1987: 953-96
15. 2-agonists: implications for drug therapy. Drugs 1994; 47: 207-22
16. Siefkin AD. Optimal pharmacologic treatment of the critically ill patient with obstructive airways disease. Am J Med 1996; 100 Suppl. 1A: 54S-61S
17. Hughs JA, Tobin MJ, Bellamy D, et al. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax 1982; 37: 667-70
18. Easton PA, Jadue C, Dhingra S, et al. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986; 315: 735-9
19. Poppius H, Salorinne Y. Comparative trial of a new anticholinergic bronchodilator, Sch 1000, and salbutamol in chronic bronchitis. BMJ 1973; 4: 134-6
20. Tashkin DP, Ashutosh K, Bleecker ER, et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: a 90-day multi-center study. Am J Med 1986; 81 Suppl. 5A: 59-67
21. Braun SR, McKenzie WN, Copeland C, et al. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airways disease. Arch Intern Med 1989; 149: 544-7
22. Koyama H, Nishimura K, Ikeda A, et al. A comparison of the bronchodilating effects of oxitropium bromide and fenoterol in patients with chronic obstructive pulmonary disease. Chest 1993; 104: 1743-7
23. Karpel JP. Bronchodilator response to anticholinergic agents in acute and stable COPD. Chest 1991; 99: 871-6
24. Gross NJ, Petty TL, Friedman M, et al. Dose response to ipratropium bromide as a nebulized solution in patients with chronic obstructive pulmonary disease: a three center study. Am Rev Respir Dis 1989; 139: 1188-91
25. Hockley B, Johnson NM. A comparison of three high dosages of ipratropium bromide in chronic asthma. Br J Dis Chest 1985; 79: 379-84
26. Ikeda A, Nishimura K, Koyama H, et al. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 62-6
27. Lightbody IM, Ingram CG, Legge JS, et al. Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis. Br J Dis Chest 1978; 72: 181-6
28. Douglas NJ, Davidson I, Sudlow MF, et al. Bronchodilatation and the site of airway resistance in severe chronic bronchitis. Thorax 1979; 34: 51-6
29. Ikeda A, Nishimura K, Koyama H, et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995; 107: 401-5
30. LeDoux EJ, Morris JF, Temple WP, et al. Standard and double dose ipratropium bromide and inhaled metaproterenol in COPD. Chest 1989; 95: 1013-6
31. Karpel JP, Pesin J, Greenberg G, et al. A comparison of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990; 98: 835-9
32. Moayyedi P, Congleton J, Page RL, et al. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995; 50: 834-7
33. Filuk RB, Easton PA, Anthonisen NR. Responses to large doses of sulbutamol and theophylline in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 132: 871-4
34. Lam A, Newhouse MT. Management of asthma and chronic airflow limitation: are methylxanthines obsolete? Chest 1990; 98: 44-52
35. Bleeker ER, Britt EJ. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. Am J Med 1991; 91 Suppl. 4A: 24S-7S
36. Nishimura K, Koyama H, Ikeda A, et al. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 1995; 107: 718-23
37. Sullivan P, Bekir S, Jaffar Z, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343: 1006-8
38. Kidney JH, Dominguez M, Taylor PM, et al. Immunomodulalion by theophylline in asthma. Am J Respir Crit Care Med 1995; 151: 1907-14
39. Rice KL, Leatherman JW, Duane PG, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease: a controlled trial. Ann Intern Med 1987; 107: 305-9
40. Morris HG. Mechanisms of glucocorticoid action in pulmonary disease. Chest 1985; 88 (2 Suppl.): 133S-41S
41. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991; 114: 216-23
42. Weir DC, Gove RI, Robertson AS, et al. Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax 1990; 45: 112-7
43. Emerman CL, Connors AF, Lukens ME, et al. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest 1989; 95: 563-7
44. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92: 753-8
45. Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation. Am J Crit Care Med 1996; 154: 407-12
46. Derenne JP, Fleury B, Pariente R. Acute respiratory failure and chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 138: 1006-33
47. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067-83
48. Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-20
49. Fagon JY, Chastre J. Severe exacerbations of COPD patients: the role of pulmonary infections. Semin Respir Infect 1996; 11: 109-18
50. Blasi F, Legnani D, Lombardo VM, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993; 6: 19-22
51. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204
52. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis: a controlled study using tetracycline. Ann Intern Med 1982; 97: 18-21
53. Sachs APE, Koëter GH, Groenier KH, et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50: 758-63
54. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273: 957-60
55. Sergysels R. Chest physiotherapy from chronic to acute respiratory failure in chronic obstructive lung disease. In: Derenne JP, Whitelaw WA, Similowski T, editors. Acute respiratory failure in chronic obstructive pulmonary disease. New York: Marcel Dekker, 1996: 615-34
56. Petty TL. The National Mucolytic Study: results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990; 97: 75-83
57. Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 1996; 109: 348-52
58. Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988; 1: 351-5
59. Hansen NC, Skriver A, Brorsen RL, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994; 88: 531-5
60. Bridgeman MM, Marsden M, Selby C, et al. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49: 670-5
61. Vilkman S, Keistinen T, Tuuponen T, et al. Age distribution of patients in hospital for chronic obstructive pulmonary disease. Age Ageing 1995; 25: 109-12
62. Chang JT, Moran MB, Cugell DW, et al. COPD in the elderly: a reversible cause of functional impairment. Chest 1995; 108: 736-40
63. Teramoto S, Fukuchi Y. Improvements in exercise capacity and dyspnoea by inhaled anticholinergic drug in elderly patients with chronic obstructive pulmonary disease. Age Ageing 1995; 24: 278-82
64. Couser JI, Guthmann R, Hamadeh MA, et al. Pulmonary rehab ilitation improves exercise capacity in elderly patients with COPD. Chest 1995; 107: 730-4
65. Nielsen-Kudsk F, Magnussen T, Jakobsen N. Pharmacokinetics of theophylline in ten elderly patients. Acta Pharmacol Toxicol Copenh 1978; 42: 226-34
66. Morris JF. Physiological changes due to age: implications for respiratory drug therapy. Drugs Aging 1994; 4: 207-20
67. Tohin MJ, Jenouri G, Danta I, et al. Response to bronchodilator drug administration by a new reservoir delivery system and a review of other auxiliary delivery systems. Am Rev Respir Med 1982; 126: 670-5